Semiannual Securities Report — FY2026 H1

During the current interim consolidated accounting period, inquiries related to capital investment increased, while extended lead times for key components became apparent and there were numerous cases in which products could not be delivered by customers’ requested delivery dates. As a result, net sales were ¥1,001 million, and the company recorded an operating loss, an ordinary loss and an interim net loss attributable to owners of the parent. Sales and profit declined in the X-ray residual stress measurement equipment business, while sales increased and profit improved, including reduced losses, in the healthcare equipment business and the optical applications and special-purpose equipment business.